Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 12/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 3/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888811 | 0.89 | ALDH1A1 (0.52) | ALDH1A1HSD17B10DHODHHPGDCDC7 | |
| SCHEMBL3893539 | 0.89 | ALDH1A1 (0.52) | ALDH1A1HSD17B10DHODHHPGDCDC7 | |
| SCHEMBL3892246 | 0.89 | ALDH1A1 (0.51) | ALDH1A1HSD17B10DHODHHPGDCDC7 | |
| SCHEMBL3891536 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HSD17B10DHODHHPGDCDC7 | |
| SCHEMBL3892448 | 0.87 | DHODH (0.53) | ALDH1A1HSD17B10DHODHHPGDCDC7 | |
| SCHEMBL3894805 | 0.87 | DHODH (0.53) | ALDH1A1HSD17B10DHODHHPGDCDC7 | |
| SCHEMBL3889705 | 0.85 | FGFR1 (0.51) | ALDH1A1HPGDCDC7DBF4MEN1 | |
| SCHEMBL3889160 | 0.83 | DHODH (0.47) | ALDH1A1HSD17B10DHODHHPGDCDC7 | |
| SCHEMBL14441472 | 0.82 | FGFR1 (0.45) | ALDH1A1CDC7DBF4 | |
| SCHEMBL2493948 | 0.80 | PIK3CD (0.46) | ALDH1A1HSD17B10DHODHHPGDCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504513-B2 | Thiazolyl-benzimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504513-B2 | Thiazolyl-benzimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504513-B2 | Thiazolyl-benzimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1991543-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203210-A1 | Thiazolyl-benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | ALDH1A1 100/4885HSD17B10 683/4885DHODH 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.